Drug Profile
RSLV 132
Alternative Names: RSLV-132Latest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator Washington University
- Developer Resolve Therapeutics
- Class Anti-inflammatories; Antihaemorrhagics; Biological proteins; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action B cell inhibitors; Interferon alpha inhibitors; Ribonuclease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Sjogren's syndrome
- Phase II Post acute COVID 19 syndrome; Subarachnoid haemorrhage; Systemic lupus erythematosus
Most Recent Events
- 20 Dec 2023 Phase-II clinical trials in Subarachnoid haemorrhage in Unknown location (Parenteral) before December 2023 (Resolve Therapeutics pipeline, December 2023)
- 21 Sep 2023 Preclinical trials in Subarachnoid haemorrhage in USA (Parenteral) (Resolve Therapeutics pipeline, September 2023)
- 19 Jul 2023 Phase-III clinical trials in Sjogren's syndrome (IV) (Resolve Therapeutics Pipeline, July 2023)